Skip to main content
CRIS logo

CRIS · Curis Inc

Track CRIS — free
$0.43 -0.04 (-9.03%) At close · Nov 20
Market Cap
$4.06M
Shares
9.51M
Volume · Nov 20 531.09K Avg daily vol (3M) 4.27M

Price & Indicators

 

Key stats

Close
$0.43
Fri 20 Nov
Open
$0.47
Fri 20 Nov
Average volume, 30 days
9.1M
shares a session
Short interest
1.0M
10.8% of shares · 1.1 days to cover
Day range
$0.42$0.49
Open $0.47 Close $0.43
52-week closing range
$0.38$27.40
Close $0.43 98.4% under the high
Short volume, last session
67%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 13
Price history
Jan 2020 to Nov 2026

Up next

Mar 18, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 13
Registration statement S-3
Registers 33,333,360 shares for resale

Curis, Inc. registered up to 33,333,360 common shares for resale by selling stockholders, including shares issuable upon exercise of October 2026 Pre-Funded Warrants and October 2026 Common Warrants sold in the October 2026 Private Placement.

Read from the first part of this long document
Source passage
This prospectus relates to the resale from time to time of up to 33,333,360 shares of common stock of Curis, Inc. by the selling stockholders listed on page 10, including their donees, pledgees, transferees or other successors-in-interest, consisting of (i) 2,574,517 shares of our common stock, par value $0.01, or the Common Stock, (ii) 14,092,163 shares of our Common Stock issuable upon the exercise of pre-funded warrants to purchase our Common Stock, or the October 2026 Pre-Funded Warrants, and (iii) 16,666,680 shares of our Common Stock issuable upon the exercise of warrants to purchase our Common Stock, or the October 2026 Common Warrants (or, in certain circumstances, pre-funded warrants). The shares of Common Stock, October 2026 Pre-Funded Warrants and October 2026 Common Warrants were sold to the selling stockholders in a private placement in October 2026, or the October 2026 Private Placement. Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Funding extends operations only into first quarter of 2027

Curis, Inc. says $5.0 million of cash plus approximately $7.5 million from the October 2026 Private Placement fund operations into the first quarter of 2027. Substantial going-concern doubt remains; Curis appealed Nasdaq’s November 2, 2026 delist determination.

Net loss $8.12M Diluted EPS -$1.94
Read from the MD&A section
4 source passages
our $5.0 million of existing cash and cash equivalents as of September 30, 2026, together with the net proceeds of approximately $7.5 million from the October 2026 Private Placement, should enable us to fund our existing operations into the first quarter of 2027. conditions and events that raise substantial doubt regarding our ability to continue as a going concern On November 2, 2026, we received a delist determination from Nasdaq for failure to comply with the minimum bid price requirement, which we have appealed. the term “Curis” refers to Curis, Inc. Open the document at this passage
Nov 13
Current report 8-K Events of Nov 12
Third-quarter loss widened with no revenue reported

Curis reported a third-quarter net loss of $8.1 million, no revenue, and $5.0 million cash as of September 30, 2026; it believes financing will fund operations into the first quarter of 2027, while 2 emavusertib studies continue enrolling.

Financial results
6 source passages
For the third quarter of 2026, Curis reported a net loss of $8.1 million or $1.94 per share on both a basic and diluted basis as compared to $7.7 million or $9.86 per share on both a basic and diluted basis, for the same period in 2025. There was no revenue reported for the quarter or the year ended September 30, 2026 due to the sale of Erivedge® royalties to Oberland in the fourth quarter of 2025. Curis's cash and cash equivalents totaled $5.0 million as of September 30, 2026, and the Company had approximately 4.1 million shares of common stock outstanding. The Company believes that the $5.0 million of existing cash and cash equivalents as of September 30, 2026, together with the net proceeds of approximately $7.5 million from the October 2026 Private Placement, should enable it to fund our existing operations into the first quarter of 2027. Curis is currently enrolling patients in 2 ongoing studies, the TakeAim CLL study (CA-4948-203, NCT07271667) and the TakeAim Lymphoma study in PCNSL (CA-4948-101, NCT03328078). Curis is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor. Open the document at this passage
Nov 12
Earnings call
86% PCNSL response rate; NDA filing planned for 2028

Curis reported an 86% response rate in seven BTK-naive primary CNS lymphoma patients and responses in 10 of 39 salvage-line patients. Full enrollment is expected in 2027, followed by an NDA filing in 2028.

5 source passages
Thank you, and welcome to Curis' third quarter 2026 business update call. The updated data show an 86% response rate in BTKI-naive patients, with six of seven patients achieving a response. For large-line patients, those patients whose disease had progressed while taking a BTK inhibitor, the updated data show a 26% response rate with 10 of 39 patients responding when treated with the Mofusertib plus BTKI combination after they had already progressed on BTKI monotherapy. we expect to be fully enrolled in the study by the end of 2027. Filing it in 2028. Open the document at this passage
Nov 6
Current report 8-K Events of Nov 2
Nasdaq issues bid-price delist determination

Nasdaq notified Curis, Inc. on November 2, 2026 that common stock closed below the minimum $1.00 per share for 30 business days. A July 6, 2026 1-for-20 reverse stock split left the company ineligible for a compliance period.

Delisting notice or listing transfer
2 source passages
On November 2, 2026, Curis, Inc. (the “Company”) received a letter (the “Delist Determination Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As the Company effected a 1-for-20 reverse stock split on July 6, 2026, the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.31M
Trailing 12 months
Net income (TTM)
−$21.54M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-60.5%
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 1,384.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$5.01M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+432.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
10.8%
Latest settlement · 1.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. PCNSL data showed meaningful response rates and support the potential for accelerated approval, while the CLL study reached 12 patients with initial data expected in December 2026. Curis also funded operations into the first quarter of 2027, but reported no revenue, larger net losses, insufficient cash for the next 12 months, and a potential PCNSL NDA filing in 2028.

Bullish
  • + Updated PCNSL data showed an 86% overall response rate in BTK-naïve patients.
  • + The combination produced a 26% overall response rate in BTKi-experienced PCNSL patients.
  • + FDA and EMA guidance indicated the registrational PCNSL study could support accelerated-approval applications.
  • + The CLL study enrolled 12 patients, with initial data expected in December 2026.
  • + Existing cash and October private-placement proceeds were expected to fund operations into the first quarter of 2027.
  • + Third-quarter research and development expense decreased to $5.6 million from $6.4 million.
Bearish
  • − Curis reported no revenue for the quarter or year ended September 30, 2026.
  • − Third-quarter net loss was $8.1 million, compared with $7.7 million in the prior-year period.
  • − Nine-month net loss was $40.9 million, compared with $26.9 million in the prior-year period.
  • − Nine-month other expense increased to $10.7 million from $1.6 million.
  • − Curis lacked sufficient cash to support current operations for the next 12 months and said it would require substantial additional funding.
  • − PCNSL full enrollment was anticipated in 2027, with an NDA filing anticipated in 2028.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −94%
below
Price vs 50-day avg −38%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +11%
trailing
6-month return −96%
trailing
YTD return −98%
this year
Relative strength −87%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $8 — 200d above 50d
Institutional flow Distributing
-28% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.82% of shares out · ▲ +134.3% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
28 holders — near 3-yr low, contrarian setup
Squeeze score 66
elevated · 0–100
Fundamentals
Excellent
Revenue growth +31%
Y/Y
EPS growth +92%
Y/Y
Free cash flow $-27.2M
Buyback $3.0M
authorized
Balance sheet $5.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 151%
annualized · 1-yr
Max drawdown −99%
past year
ATR 38.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed May 12, 2026
Gross proceeds from the exercise of the January 2026 PIPE Financ · later this year $20.2M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−94% Bearish
Price vs 50-day avg
−38% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $8 — 200d above 50d
Institutional flow Distributing
-28% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.82% of shares out · ▲ +134.3% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
28 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $27
vs 200-day avg -94% vs 50-day avg -38%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
BTK-naïve patients 7 July 2026 —
BTKi-experienced patients 39 July 2026 —
ongoing studies 2 currently —
Shares of common stock sold under the 2024 Sales Agreement 107,449 the three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRIS
Curis Inc
this stock
$4.06M — +31.5% — 10.8%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
28
% held
12.2%
Net QoQ
+392.7K sh
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
1.0M
Days to cover
1.1d
Change
+590.1K sh
View
Short Volume
Short vol %
67%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
272.8K
Value
$150.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
46.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$9.4M
Net income (FY)
$-7.6M
EPS diluted
$-11.60
View
Buybacks
Authorized
$3.0M
View
Filings
SEC Filings
Latest
S-3
Filed
Nov 13, 2026
This year
31

Curis, Inc. registered up to 33,333,360 common shares for resale by selling stockholders, including shares issuable upon exercise of October 2026 Pre-Funded Warrants and October 2026 Common Warrants sold in the October 2026 Private Placement.

View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Curis Provides Third Quarter 2026…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
CRIS -4.0% +10.5% -95.7% -28.8% -97.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +4.5% +19.8% -86.6% -20.1% -99.0%

Capital returns

Buyback program · as of Dec 31, 2019
Authorized
$3.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1108205 CUSIP 231269408 13F (30d) 52 filings 29 filers Visit website Investor relations